bluebird bio (NASDAQ:BLUE) Share Price Crosses Below 200-Day Moving Average - What's Next?

bluebird bio, Inc. (NASDAQ:BLUE - Get Free Report)'s share price passed below its two hundred day moving average during trading on Thursday . The stock has a two hundred day moving average of $10.29 and traded as low as $6.20. bluebird bio shares last traded at $7.25, with a volume of 286,502 shares.

Analyst Upgrades and Downgrades

Several equities research analysts have commented on the company. StockNews.com assumed coverage on bluebird bio in a report on Friday, December 20th. They issued a "sell" rating on the stock. JPMorgan Chase & Co. downgraded bluebird bio from a "neutral" rating to an "underweight" rating in a report on Friday, November 15th. Royal Bank of Canada reaffirmed a "sector perform" rating and set a $80.00 price target on shares of bluebird bio in a report on Friday, November 15th. Barclays upped their price target on bluebird bio from $2.00 to $40.00 and gave the company an "overweight" rating in a report on Tuesday, December 31st. Finally, Bank of America downgraded bluebird bio from a "buy" rating to a "neutral" rating and lowered their price target for the company from $60.00 to $10.00 in a report on Friday, November 15th. Three equities research analysts have rated the stock with a sell rating, five have assigned a hold rating and two have assigned a buy rating to the company's stock. Based on data from MarketBeat.com, the company has an average rating of "Hold" and an average price target of $49.14.

bluebird bio Stock Performance

The company has a market cap of $70.66 million, a PE ratio of -0.19 and a beta of 0.68. The company has a debt-to-equity ratio of 0.37, a current ratio of 0.51 and a quick ratio of 0.33. The business has a 50-day moving average of $7.90 and a 200 day moving average of $9.87.

Institutional Trading of bluebird bio

Hedge funds have recently bought and sold shares of the company. Regeneron Pharmaceuticals Inc. purchased a new stake in bluebird bio during the fourth quarter valued at $175,000. Verition Fund Management LLC purchased a new stake in bluebird bio during the third quarter valued at $42,000. SG Americas Securities LLC increased its position in bluebird bio by 152.4% during the third quarter. SG Americas Securities LLC now owns 122,855 shares of the biotechnology company's stock valued at $64,000 after acquiring an additional 74,185 shares during the last quarter. Captrust Financial Advisors increased its position in bluebird bio by 48.2% during the third quarter. Captrust Financial Advisors now owns 237,648 shares of the biotechnology company's stock valued at $123,000 after acquiring an additional 77,293 shares during the last quarter. Finally, Barclays PLC increased its position in bluebird bio by 273.7% during the third quarter. Barclays PLC now owns 252,062 shares of the biotechnology company's stock valued at $130,000 after acquiring an additional 184,605 shares during the last quarter. Hedge funds and other institutional investors own 87.43% of the company's stock.

About bluebird bio

bluebird bio, Inc, a biotechnology company, researches, develops, and commercializes gene therapies for severe genetic diseases. Its product candidates for severe genetic diseases include ZYNTEGLO (betibeglogene autotemcel) for the treatment of transfusion-dependent ß-thalassemia; lovotibeglogene autotemcel for the treatment of sickle cell disease (SCD); and SKYSONA (elivaldogene autotemcel) to treat cerebral adrenoleukodystrophy.